Dr. Mamdani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4100 John R St
Detroit, MI 48201Phone+1 313-576-8709- Is this information wrong?
Summary
- Dr. Hirva Mamdani is a medical oncologist specializing in treatment of thoracic malignancies, including lung cancer, mesothelioma, and esophageal cancer. She is affiliated with Karmanos Cancer Institute - an NCI designated comprehensive cancer center. Dr. Mamdani received her medical degree from M.P. Shah Medical College in India. She completed her residency from Wayne State University, Detroit MI and fellowship training from Indiana University, Indianapolis IN. Dr. Mamdani is involved in a large number of national and global clinical trials evaluating novel therapeutic agents for the treatment of thoracic cancers. Her areas of research interest include immunotherapy and DNA repair pathways.
Education & Training
Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2014 - 2017
Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine, 2011 - 2014
M.P. Shah Medical CollegeClass of 2009
Certifications & Licensure
MI State Medical License 2016 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Investigator Award Immunooncology Young Investigators’ Forum, 2019
- Young Investigator Award Young Investigators’ Forum in Lung Cancer, 2019
Clinical Trials
- A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer Start of enrollment: 2022 Apr 15
Roles: Principal Investigator, Contact
- NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Start of enrollment: 2020 Jun 10
Roles: Contact
- Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. Start of enrollment: 2022 Aug 26
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Influence ofComutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in-Mutant Non-Small-Cell Lung Cancer.Naqash, A., Floudas, C., Aber, E., Maoz, A., Nassar, A., Adib, E., Choucair, K., Xiu, J., Baca, Y., Ricciuti, B., Alessi, J., Awad, M., Kim, C., Judd, J., Raez, L., Lo...> ;JCO Precision Oncology. 2024 Feb 1
- Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.Chen, J., Bearz, A., Kim, D., Mamdani, H., Bauman, J., Chiari, R., Ou, S., Solomon, B., Soo, R., Felip, E., Shaw, A., Thurm, H., Clancy, J., Lee, K., O'Gorman, M., Tan...> ;Clinical Pharmacokinetics. 2024 Feb 1
- Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299.Xi, M., Dudek, A., Scilla, K., Mamdani, H., Creelan, B., Saltos, A., Tanvetyanon, T., Chiappori, A.> ;JTO Clinical and Research Reports. 2023 Dec 1
- Join now to see all
Lectures
- Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Two-year follow-up results from Big Ten Cance...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination (HR) defective or loss of heterozygosity (LOH...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Results from big ten cancer research consorti...ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Join now to see all
Press Mentions
Early Detection Is Key for This Common Form of CancerNovember 21st, 2022- Karmanos Cancer Institute Partners with Nation's Top Cancer Organizations to Endorse Initiative to Increase Lung Cancer Screening in the United StatesNovember 1st, 2022
- Simple Lung Cancer Screening Test Is Easy, Painless — and Could Save Your LifeNovember 22nd, 2022
Professional Memberships
- Member
- Member
- Member
Other Languages
- Hindi, Gujarati
Hospital Affiliations
Karmanos Cancer CenterDetroit, Michigan
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
